Summary
Lepirudin is an anticoagulant that functions as a direct thrombin inhibitor.
 | |
| Clinical data | |
|---|---|
| Trade names | Refludan |
| AHFS/Drugs.com | Monograph |
| Routes of administration | SQ or IV |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 100 |
| Elimination half-life | ~1.3 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number |
|
| IUPHAR/BPS |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) |
|
| Chemical and physical data | |
| Formula | C288H448N80O110S6 |
| Molar mass | 6983.56 g·mol−1 |
  (what is this?) (verify) | |
Brand name: Refludan, Generic: Lepirudin rDNA for injection.
Lepirudin is a recombinant hirudin[1] derived from yeast cells. Lepirudin is almost identical to hirudin extracted from Hirudo medicinalis, having the amino acid sequence LTYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ with disulfide bridges at Cys6-Cys14, Cys16-Cys28 and Cys22-Cys39, and differs from by the substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63.
Lepirudin may be used as an anticoagulant when heparins (unfractionated or low-molecular-weight) are contraindicated because of heparin-induced thrombocytopenia.
Market withdrawal edit
Bayer announced that it ceased the production of lepirudin (Refludan) on May 31, 2012. At the time of the announcement, the company expected that supply from wholesalers was going to be depleted by mid-2013.[2]
References edit
- ^ Askari AT, Lincoff AM (October 2009). Antithrombotic Drug Therapy in Cardiovascular Disease. Springer. pp. 440–. ISBN 978-1-60327-234-6. Retrieved 30 October 2010.
- ^ "Discontinued Drug Bulletin: Lepirudin Injection". American Society of Health System Pharmacists (ASHP). 23 May 2012. Archived from the original on 2014-07-23.
Further reading edit
- Smythe MA, Stephens JL, Koerber JM, Mattson JC (October 2005). "A comparison of lepirudin and argatroban outcomes". Clinical and Applied Thrombosis/Hemostasis. 11 (4): 371–374. doi:10.1177/107602960501100403. PMID 16244762.
- Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, et al. (September 2006). "Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin". Blood. 108 (5): 1492–1496. doi:10.1182/blood-2006-02-001057. PMID 16690967.
- Lubenow N, Eichler P, Lietz T, Greinacher A (November 2005). "Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3". Journal of Thrombosis and Haemostasis. 3 (11): 2428–2436. doi:10.1111/j.1538-7836.2005.01623.x. PMID 16241940.
External links edit
- Diseases Database (DDB): 30082